Virion Therapeutics, LLC

Virion Therapeutics, LLC is at the forefront of biotechnology research, dedicated to revolutionizing immunotherapy treatments for cancer and infectious diseases. Driven by cutting-edge science, Virion Therapeutics is focused on developing novel, adaptable, and accessible CD8+ T cell-based technologies. The company's innovative approach combines established methodologies to elicit a superior CD8+ T cell response, holding immense potential across a range of cancers and chronic infectious diseases. Virion Therapeutics, LLC's proprietary technology fuels a robust pipeline, with its lead product, VRON-0200, currently under investigation as a potential functional cure for the treatment of chronic hepatitis B virus (HBV).

Virion Therapeutics is located at 7 Creek Bend Court, Newark, DE 19711, US. Virion Therapeutics believes that a future free of cancer and chronic infectious diseases is within reach. Novel genetically encoded checkpoint modifiers are delivered alongside optimized target-specific antigens via an immunogenic and adaptable viral vector platform that promotes potent, prolonged, and broad CD8+ T cell responses.

Virion Therapeutics, LLC has assembled a world-class team with extensive preclinical and clinical expertise in antiviral, vaccine, oncology, and immuno-oncology. The company is committed to advancing its technology and expanding its impact on global health. We encourage the management team at Virion Therapeutics, LLC, to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.